TURNOVER (x1000 EUR)
NET PROFIT (x1000 EUR)
EMPLOYEES
Bio Vitos Pharma AB
Closing information (x1000 EUR)
| Closing information | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Turnover |
10
|
270
|
119 |
| Financial expenses |
0
|
0
|
0 |
| Earnings before taxes |
-1,747
|
-1,160
|
-1,339 |
| EBITDA |
-289
|
-316
|
-699 |
| Total assets |
1,420
|
3,057
|
2,377 |
| Current assets |
33
|
461
|
469 |
| Current liabilities |
34
|
91
|
137 |
| Equity capital |
1,386
|
2,966
|
2,240 |
| - share capital |
499
|
386
|
278 |
| Employees (average) |
1
|
1
|
5 |
Financial ratios
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Solvency |
97.6%
|
97.0%
|
94.2% |
| Turnover per employee |
10
|
270
|
24 |
| Profit as a percentage of turnover |
-17470.0%
|
-429.6%
|
-1125.2% |
| Return on assets (ROA) |
-123.0%
|
-37.9%
|
-56.3% |
| Current ratio |
97.1%
|
506.6%
|
342.3% |
| Return on equity (ROE) |
-126.0%
|
-39.1%
|
-59.8% |
| Change turnover | |||
| Change turnover % | 18% | ||
| Chg. No. of employees | |||
| Chg. No. of employees % | -17% |
Total value of public sale
| Fiscal year | 2024/12 | 2023/12 (consolidated) | 2022/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.